NTPC

Refer to important disclosures at the end of this report

Strengthening the RE portfolio

- NTPC continues to win solar/RE bids on the back of its low cost of funding, significantly strong cash flows and project management abilities. NTPC has won 500MW in SECI's recent 1,785MW Rajasthan Tranche IV bid. Six players had submitted their bids in the Rs2.17-2.18 range, which highlights stiff competition.
- For the last one and a half years, management has been focused on RE. On its base thermal assets, we believe RoE will improve as more plants are commissioned. In our view, these factors will lead to a re-rating. NTPC's ability to source low-cost funds will enable it to resourcefully attain its RE plan. NTPC is expected to add ~35GW of RE capacity by 2027. Moreover, ~10GW of thermal units will be added in the next few years.
- We maintain Buy on NTPC with a Dec'22 TP of Rs180. At CMP, the stock trades at 0.86x/0.8x PB on FY23E/FY24E with RoE in the 12-12.5% range. NTPC plans to float an IPO of its RE business in the next 1-2 years.
- Strengthening RE portfolio: NTPC aims to achieve 15GW/35GW/60GW of RE capacity by FY24/FY27/FY32. It presently has ~7GW of installed/under-construction/bids won in the RE space. It has been very competitive in bidding for the majority of RE projects lately. NTPC has doubled its RE portfolio in the last 18 months, with ~7GW of projects currently either commissioned, under implementation, or bid successfully. NTPC has recently won 500MW/1.9GW in the SECI Tranche IV (Rajasthan) and auction of CPSU Scheme-II (tranche-III of 5GW) in Sept'21and Dec'21, respectively. In FY21, NTPC had a 15% market share in RE bids in the country. NTPC has got approval for 4.75GW UMREPP in the Rann of Kutch, with another ~10GW UNREPP in the development pipeline. NTPC has signed an MoU with ONGC to form a joint venture for the development of offshore wind projects. It has also inked a pact with DVC to develop solar plants on DVC reservoirs and land. NTPC's recent success in various solar bids indicates a change in its stance and competitiveness. It has strengthened its hydro portfolio with the acquisition of THDC and NEEPCO. NTPC plans to float an IPO of its RE business in the next 1-2 years.
- Generation remains healthy: Generation from NTPC units has been healthy at 11.5% YoY so far in Q3FY22 (till 22nd Dec'21), with a 2-year CAGR of ~9%. YTD growth stood at 13.6% due to the low base in H1FY21.
- Valuation, outlook and risk: We maintain our SoTP-based Dec'22 TP of Rs180. At CMP, the stock trades at 0.86x/0.8x PB on FY23E/FY24E. With RoE in the 12-12.5% range and a 7% EPS CAGR over FY21-FY24E, we believe the stock is attractively priced. In our view, strengthening the RE portfolio and increasing the share of RE should drive rerating.

Financial Snapshot (Standalone)

(Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	9,77,004	9,92,067	10,52,055	11,26,019	12,00,773
EBITDA	2,70,927	2,88,034	3,41,859	3,69,738	3,84,060
EBITDA Margin (%)	27.7	29.0	32.5	32.8	32.0
APAT	1,01,127	1,38,067	1,44,028	1,58,187	1,75,551
EPS (Rs)	10.2	14.2	14.9	16.3	18.1
EPS (% chg)	(13.9)	39.3	4.3	9.8	11.0
ROE (%)	9.2	11.9	11.7	12.0	12.3
P/E (x)	11.9	8.5	8.2	7.4	6.7
EV/EBITDA (x)	10.3	9.7	8.3	7.5	6.8
P/BV (x)	1.1	1.0	0.9	0.9	0.8



СМР	Target Price
Rs 121 as of (December 25, 2021)	Rs 180 (∎) 12 months
Rating	Upside
BUY (∎)	48.5 %

Change in Estimates

onunge in Estimate	0		
EPS Chg FY22E/FY2	23E (%)		-/-/
Target Price change	(%)		-
Target Period (Month	ıs)		12
Previous Reco			BUY
Emkay vs Consens	us		
EPS Es	timates	;	
	FY2	2E	FY23E
Emkay	1	4.9	16.3
Consensus	1	5.6	17.1
Mean Consensus TP	' (12M)		Rs 168
Stock Details			
Bloomberg Code		N	TPC IN
Face Value (Rs)			10
Shares outstanding (mn)		9,697
52 Week H/L			155 / 88
M Cap (Rs bn/USD b	n)	1,176	/ 15.67
Daily Avg Volume (ne	os.)	17,0	016,650
Daily Avg Turnover (US\$ mr)	31.1
Chanabaldina Datta		104	
Shareholding Patter	m Sep	21	51.1%
Promoters			13.5%
Flls			
DIIs			32.0%
Public and Others			3.4%
Price Performance			
(%) 1M	3M	6M	12M
Absolute (10)	(2)	3	21
Rel. to Nifty (8)	2	(5)	(2)
Relative price chart			
¹⁵⁰ Rs		Л	% [20
136 -		1/2h	- 12
122 -	addyn o	1 N	4
108 m Marth	- WV	M	-4
94 -	7)	12
80			
Dec-20 Feb-21 Apr-21 Jur	-21 Aug-2	1 Oct-2	
NTPC (LHS)		Rel to Nifty	(RHS)
Source: Bloomberg This report is solely produ following person(s) are res production of the recomm	sponsible		obal. The
Abhineet Anand			
abhineet.anand@em	kayglob	al.con	ı
+91 22 6624 2466	, 9 6		
Abhishek Mody			
abhishek.mody@eml	kaygloba	al.com	1
· · · · · · · · · · · · · · · · · · ·			
+91 22 6624 2491			

Source: Contrary, EmbauBestarcheam.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 12:09 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Key Financials (Standalone)

Income Statement

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	9,77,004	9,92,067	10,52,055	11,26,019	12,00,773
Expenditure	7,06,077	7,04,034	7,10,195	7,56,282	8,16,714
EBITDA	2,70,927	2,88,034	3,41,859	3,69,738	3,84,060
Depreciation	86,229	1,04,118	1,14,939	1,32,973	1,35,489
EBIT	1,84,699	1,83,916	2,26,920	2,36,765	2,48,570
Other Income	76,068	47,996	38,082	45,876	52,219
Interest expenses	67,820	74,590	84,967	84,906	81,350
РВТ	1,92,947	1,57,321	1,80,035	1,97,734	2,19,439
Тах	91,820	19,254	36,007	39,547	43,888
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
Reported Net Income	1,01,127	1,38,067	1,44,028	1,58,187	1,75,551
Adjusted PAT	1,01,127	1,38,067	1,44,028	1,58,187	1,75,551

Balance Sheet

Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
Equity share capital	98,946	96,967	96,967	96,967	96,967
Reserves & surplus	10,36,749	10,92,888	11,79,305	12,74,217	13,79,548
Net worth	11,35,694	11,89,855	12,76,272	13,71,184	14,76,515
Minority Interest	0	0	0	0	0
Loan Funds	16,05,881	16,40,894	16,99,338	16,98,129	16,26,996
Net deferred tax liability	80,940	91,610	91,610	91,610	91,610
Total Liabilities	28,22,515	29,22,358	30,67,219	31,60,923	31,95,120
Net block	15,68,113	16,44,489	17,19,049	19,46,743	18,61,587
Investment	2,64,009	2,86,257	2,96,257	3,06,257	3,16,257
Current Assets	7,10,960	7,47,062	7,78,704	8,50,342	9,66,584
Cash & bank balance	22,091	23,384	37,572	93,854	1,94,386
Other Current Assets	1,75,011	1,96,715	1,96,715	1,96,715	1,96,715
Current liabilities & Provision	4,54,159	5,09,834	5,21,676	5,26,638	5,33,192
Net current assets	2,56,800	2,37,228	2,57,028	3,23,705	4,33,392
Misc. exp	0	0	0	0	0
Total Assets	28,22,515	29,22,359	30,67,219	31,60,923	31,95,120

Cash Flow					
Y/E Mar (Rs mn)	FY20	FY21	FY22E	FY23E	FY24E
PBT (Ex-Other income) (NI+Dep)	1,16,879	1,09,326	1,41,953	1,51,858	1,67,220
Other Non-Cash items	0	0	0	0	0
Chg in working cap	(48,854)	31,535	(5,612)	(10,395)	(9,155)
Operating Cashflow	2,15,840	2,70,578	3,43,615	3,69,963	3,86,527
Capital expenditure	(1,45,661)	(2,01,286)	(2,30,000)	(1,50,000)	(50,000)
Free Cash Flow	70,179	69,291	1,13,615	2,19,963	3,36,527
Investments	(1,32,550)	(22,248)	(10,000)	(10,000)	(10,000)
Other Investing Cash Flow	(70,326)	2,494	(47,374)	(54,167)	(59,511)
Investing Cashflow	(2,72,468)	(1,73,044)	(2,49,292)	(1,68,292)	(67,292)
Equity Capital Raised	0	(1,979)	0	0	0
Loans Taken / (Repaid)	2,53,871	35,013	58,444	(1,209)	(71,133)
Dividend paid (incl tax)	(29,684)	(55,311)	(57,611)	(63,275)	(70,221)
Other Financing Cash Flow	(99,092)	628	4,000	4,000	4,000
Financing Cashflow	57,276	(96,239)	(80,134)	(1,45,390)	(2,18,703)
Net chg in cash	647	1,294	14,189	56,281	1,00,533
Opening cash position	21,443	22,091	23,384	37,572	93,854
Closing cash position	22,091	23,385	37,573	93,853	1,94,387

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 12:09 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

Profitability (%)	FY20	FY21	FY22E	FY23E	FY24E
EBITDA Margin	27.7	29.0	32.5	32.8	32.0
EBIT Margin	18.9	18.5	21.6	21.0	20.7
Effective Tax Rate	47.6	12.2	20.0	20.0	20.0
Net Margin	10.4	13.9	13.7	14.0	14.6
ROCE	9.9	8.1	8.8	9.1	9.5
ROE	9.2	11.9	11.7	12.0	12.3
RoIC	11.5	10.0	12.0	11.5	11.6
Per Share Data (Rs)	FY20	FY21	FY22E	FY23E	FY24E
EPS	10.2	14.2	14.9	16.3	18.1
CEPS	18.9	25.0	26.7	30.0	32.1
BVPS	114.8	122.7	131.6	141.4	152.3
DPS	3.0	5.7	5.9	6.5	7.2
Nolvetiene (v)	EV20	EV04	EVODE	EVODE	
Valuations (x)	FY20	FY21	FY22E	FY23E	FY24E
PER	11.9	8.5	8.2	7.4	6.7
P/CEPS	6.4	4.9	4.5	4.0	3.8
P/BV	1.1 2.8	1.0	0.9	0.9	0.8
EV / Sales EV / EBITDA	2.0	2.8 9.7	2.7 8.3	2.5 7.5	2.2 6.8
	2.5	9.7 4.7			
Dividend Yield (%)	2.0	4.7	4.9	5.4	6.0
Gearing Ratio (x)	FY20	FY21	FY22E	FY23E	FY24E
Net Debt/ Equity	1.4	1.4	1.3	1.2	1.0
Net Debt/EBIDTA	5.8	5.6	4.8	4.3	3.7
Working Cap Cycle (days)	87.7	78.7	76.1	74.5	72.7
Growth (%)	FY20	FY21	FY22E	FY23E	FY24E
Revenue	8.2	1.5	6.0	7.0	6.6
EBITDA	19.0	6.3	18.7	8.2	3.9
EBIT	19.0	(0.4)	23.4	4.3	5.0
PAT	(13.9)	36.5	4.3	9.8	11.0
Quarterly (Rs mn)	Q2FY21	Q3FY21	Q4FY21	Q1FY22	Q2FY22
Revenue	2,46,771	2,45,093	2,65,669	2,60,385	2,83,290
EBITDA	71,833	73,671	65,078	74,389	72,244
EBITDA Margin (%)	29.1	30.1	24.5	28.6	25.5
PAT	35,047	33,153	44,792	31,456	32,119
1711	3.6	3.4	4.6	3.2	3.3
FPS (Rs)		•		0.2	
EPS (Rs) Source: Company, Emkay Research					
	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21
Source: Company, Emkay Research	Sep-20 51.0	Dec-20 51.1	Mar-21 51.1	Jun-21 51.1	-
Source: Company, Emkay Research Shareholding Pattern (%) Promoters	-				51.1
Source: Company, Emkay Research Shareholding Pattern (%)	51.0	51.1	51.1	51.1	Sep-21 51.1 13.5 32.0

Source: Capitaline

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 12:09 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY TABLE

Closing Price	ТР	Period (months)	Rating	Analyst
133	180	12m	Buy	Abhineet Anand
141	180	12m	Buy	Abhineet Anand
118	180	12m	Buy	Abhineet Anand
118	179	12m	Buy	Abhineet Anand
	Price 133 141 118	Price IP 133 180 141 180 118 180	Price IP (months) 133 180 12m 141 180 12m 118 180 12m	Price IP (months) Rating 133 180 12m Buy 141 180 12m Buy 118 180 12m Buy

Source: Company, Emkay Research

RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 12:09 PM

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%
SELL	Below -5%

Completed Date: 27 Dec 2021 08:41:37 (SGT) Dissemination Date: 27 Dec 2021 08:42:37 (SGT)

Sources for all charts and tables are Emkay Research unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL . All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

• This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

• Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

Disclaimer for U.S. persons only: This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investors. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 12:09 PM

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate¹ does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or have dinacial interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report-:

- 1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of December 27, 2021
- 2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- 4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of December 27, 2021.
- 5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the December 27, 2021
- 6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services form securities recommended in this report (subject company) in the past 12 months.
- 7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
- 8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the December 27, 2021

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 12:09 PM

RESTRICTIONS ON I	DISTRIBUTION
General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608-610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

Emkay Global Financial Services Ltd. CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 12/27/2021 12:09 PM

Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<BO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.